World's Best Scientists 2026 revealed!
Gynecologic Oncology
H-index 50

Gynecologic Oncology

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Medicine 228 506 1828 50

Additional Metrics

Number of Best Scientists*: 758
Documents by Best Scientists*: 2065
Top 100 Ranked Scientists*: 16
SCIMAGO H-index: 192
SCIMAGO SJR: 1.881
Impact Factor: 4.1

Overview

Top Research Topics at Gynecologic Oncology?

The journal mainly deals with areas of study such as Internal medicine, Oncology, Surgery, Ovarian cancer and Chemotherapy. Gynecologic Oncology links adjacent topics like Internal medicine with Gastroenterology. The Oncology research presented in it explores the relationship between Gynecology and the closely related topic of Obstetrics.

The research on Surgery discussed in Gynecologic Oncology draws on the closely related field of Cervical cancer. It connects research in Cervical cancer with the related topic of Radiology. Gynecologic Oncology investigates Ovarian cancer research which frequently intersects with Cancer research.

It features Chemotherapy research that overlaps with concepts in Regimen. The Carcinoma research presented falls under the domain of Pathology. The studies in Pathology featured incorporate elements of Adenocarcinoma, Metastasis and Ovary.

  • Internal medicine (38.01%)
  • Oncology (27.04%)
  • Surgery (24.18%)

What are the most cited papers published in the journal?

  • MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer (1910 citations)
  • Two pathogenetic types of endometrial carcinoma (1559 citations)
  • A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. (1213 citations)

Research areas of the most cited articles at Gynecologic Oncology:

The published articles cover a variety of subjects, including Surgery, Internal medicine, Ovarian cancer, Carcinoma and Oncology. The published articles explore research in Surgery alongside concepts in Cervical cancer and other areas of study in Cervix, Radiology and Radical surgery. The journal articles focus on Internal medicine but the discussions also offer insight into other areas such as Gastroenterology and Gynecology.

What topics the last edition of the journal is best known for?

  • Internal medicine
  • Cancer
  • Surgery

The previous edition focused in particular on these issues:

The aim of Gynecologic Oncology is to expand the discussion of research in Internal medicine, Oncology, Ovarian cancer, Cancer and Endometrial cancer. Gynecologic Oncology explores research in Internal medicine and the adjacent study of Gastroenterology. Topics in Oncology explored in Gynecologic Oncology were investigated in conjunction with research in Bevacizumab, Carcinoma, Clinical trial and Hazard ratio.

It explores issues in Ovarian cancer which can be linked to other research areas like Cancer research, Serous fluid, PARP inhibitor and Genetic testing. The Endometrial cancer works featured in Gynecologic Oncology incorporate elements from Hysterectomy and Sentinel lymph node. In it, researchers investigate the Stage (cooking) study as part of research in the field of Surgery.

The most cited articles from the last journal are:

  • Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers. (13 citations)
  • Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies - A systematic review of test accuracy. (9 citations)
  • Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. (8 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Gynecologic Oncology (based on the number of publications) are:

  • Nadeem R. Abu-Rustum (338 papers) published 19 papers at the last edition, 6 more than at the previous edition,
  • Dennis S. Chi (313 papers) published 11 papers at the last edition, 3 less than at the previous edition,
  • Richard R. Barakat (261 papers) published 1 paper at the last edition,
  • David E. Cohn (227 papers) published 13 papers at the last edition, 5 more than at the previous edition,
  • Mario M. Leitao (226 papers) published 11 papers at the last edition, 2 less than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Gynecologic Oncology (based on the number of publications) are:

  • University of Texas MD Anderson Cancer Center (1112 papers) published 62 papers at the last edition, 14 more than at the previous edition,
  • Memorial Sloan Kettering Cancer Center (890 papers) published 52 papers at the last edition, 8 more than at the previous edition,
  • Harvard University (707 papers) published 51 papers at the last edition, 11 more than at the previous edition,
  • Mayo Clinic (527 papers) published 32 papers at the last edition, 5 less than at the previous edition,
  • Roswell Park Cancer Institute (489 papers) published 18 papers at the last edition, 7 more than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 7.41% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 28.75% were posted by at least one author from the top 10 institutions publishing in the journal. Another 16.43% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 19.51% of all publications and 35.32% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Opportunities in Gynecologic Oncology

While discussing various research topics in Gynecologic Oncology, it may be beneficial to shed some light on the professional careers in this field. Besides the commitment to compelling and robust research studies, those interested in Gynecologic Oncology will also find a variety of rewarding career prospects - ranging from professors to clinical doctors and registered nurses specializing in Oncology.

However, the pathway to becoming a professional in this field may not be straightforward. For instance, to become a registered nurse specializing in Oncology, one would usually need to acquire specific qualifications, pass the licensing exams, and gain relevant experience.

If you want to understand more about the practical journey, you can check out this comprehensive guide on how to become a registered nurse in Arkansas. Even though it is state-specific, it offers valuable insights that can apply to many other geographic locations. The pathway to a rewarding career in Gynecologic Oncology often starts with nursing, which will allow you to gain firsthand experience and understand the practical aspects of the discipline.

Top Publications

  • Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)

    Alessandro D. Santin;Wei Deng;Michael Frumovitz;Natalia Buza

    (2020)
    138 Citations
  • Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.

    (2022)
    121 Citations
  • Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

    (2021)
    113 Citations
  • Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

    David M. O'Malley;Ursula A. Matulonis;Michael J. Birrer;Cesar M. Castro

    (2020)
    104 Citations
  • Low-grade serous ovarian cancer: State of the science

    Brian Slomovitz;Charlie Gourley;Mark S. Carey;Anais Malpica

    (2020)
    98 Citations
  • Pembrolizumab treatment of advanced cervical cancer: updated results from the phase II KEYNOTE-158 study

    Hyun Chung;Jean-Pierre Delord;Ruth Perets;Antoine Italiano

    (2021)
    96 Citations
  • Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer

    David M. O'Malley;Ana Oaknin;Bradley J. Monk;Frédéric Selle

    (2021)
    88 Citations
  • Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification

    Soyoun Rachel Kim;Basile Tessier Cloutier;Samuel Leung;Dawn Cochrane

    (2020)
    87 Citations
  • Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes.

    Kim E. Kortekaas;Esther Bastiaannet;Helena C. van Doorn;Peggy J. de Vos van Steenwijk

    (2020)
    86 Citations
  • Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

    (2023)
    85 Citations

Related Online Degrees & Career Pathways

For those interested in expanding their expertise beyond traditional medical studies, numerous online degree options offer flexible learning paths tailored to healthcare professionals. One popular route is pursuing cahme-accredited online mha programs, which focus on healthcare management and administration. These programs prepare students for leadership roles within hospitals, clinics, and other healthcare organizations.

Nurses aiming for advanced clinical or non-clinical roles might consider dnp online no clinicals programs. These online Doctor of Nursing Practice degrees provide specialized training without the need for in-person clinical hours, ideal for working professionals who require flexibility.

For those interested in research or executive positions, a phd in healthcare administration online offers advanced knowledge in health systems, policy, and organizational leadership. This degree helps open doors to academia, consulting, and high-level administrative careers.

Pharmacists seeking convenience and advanced credentials may explore pharm d online programs. These degrees provide comprehensive pharmaceutical education through digital platforms, making it easier to balance professional and personal commitments.

Best Scientists Contributing to This Journal

Recently Published Articles